Our news
Crossject will be attending J.P. Morgan Healthcare conference
January 13-16 2020, Crossject will be in San Francisco around the J.P. Morgan Healthcare Conference, to meet with American pharmaceutical companies.
Read more
Cooperative agreement signed between Crossject and the US Department of Defense
Crossject and the US Department of Defense have signed a cooperative research and development agreement for Zeneo® Midazolam
ZENEO® Midazolam earns the orphan drug designation
The FDA has granted Orphan Drug designation to ZENEO® Midazolam for the treatment of status epileptics.
ZENEO® receives the JANUS
Crossject is proud to announce that ZENEO® received the 2017 JANUS Prospective award from the French Institute of Design.